LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.

Eytan Ben-AmiRaul E PerretYing HuangFélicie CourgeonPrafulla C GokhaleAudrey Laroche-ClaryBenjamin K EschleValérie VelascoFrançois Le LoarerMarie-Paule AlgeoJames PurcellGeorge D DemetriAntoine Italiano

Published in: Cancers (2020)

We provide the first preclinical evidence that LRRC15 targeting with an antibody-drug conjugate is a promising strategy in LRRC15-positive STS. ABBV-085 is being evaluated in an ongoing clinical trial in STS and other malignancies.

Keyphrases

cancer therapy
clinical trial
soft tissue
drug delivery
high grade
open label
mesenchymal stem cells
bone marrow